MicroRNAs

Novel Molecular Targets and Response Modulators of Statin Therapy

Mohammad Mohajeri, Maciej Banach, Stephen Atkin, Alexandra E. Butler, Massimiliano Ruscica, Gerald F. Watts, Amirhossein Sahebkar

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) is a major cause of death globally. Addressing cardiovascular risk factors, particularly dyslipidemia, represents the most robust clinical strategy towards reducing the CVD burden. Statins inhibit 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and represent the main therapeutic approach for lowering cholesterol and reducing plaque formation/rupture. The protective effects of statins extend beyond lowering cholesterol. MicroRNAs (miRNAs or miRs), small noncoding regulatory RNAs, likely mediate the positive pleiotropic effects of statins via modulation of lipid metabolism, enhancement of endothelial function, inhibition of inflammation, improvement of plaque stability, and immune regulation. miRNAs are implicated in statin-related interindividual variations in therapeutic response, directly via HMG-CoA reductase, or indirectly through targeting cytochrome P450 3A (CYP3A) functionality and proprotein convertase subtilisin/kexin type9 (PCSK9) biology.

Original languageEnglish
JournalTrends in Pharmacological Sciences
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
MicroRNAs
Modulators
Cardiovascular Diseases
Cholesterol
Proprotein Convertases
Hydroxymethylglutaryl CoA Reductases
Subtilisin
Cytochrome P-450 CYP3A
Small Untranslated RNA
Coenzyme A
Therapeutics
Dyslipidemias
Lipid Metabolism
Rupture
Cause of Death
Oxidoreductases
Modulation
RNA
Inflammation

Keywords

  • cardiovascular disease
  • interindividual variation
  • microRNAs
  • pleiotropic effects
  • Statins

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

MicroRNAs : Novel Molecular Targets and Response Modulators of Statin Therapy. / Mohajeri, Mohammad; Banach, Maciej; Atkin, Stephen; Butler, Alexandra E.; Ruscica, Massimiliano; Watts, Gerald F.; Sahebkar, Amirhossein.

In: Trends in Pharmacological Sciences, 01.01.2018.

Research output: Contribution to journalArticle

Mohajeri, Mohammad ; Banach, Maciej ; Atkin, Stephen ; Butler, Alexandra E. ; Ruscica, Massimiliano ; Watts, Gerald F. ; Sahebkar, Amirhossein. / MicroRNAs : Novel Molecular Targets and Response Modulators of Statin Therapy. In: Trends in Pharmacological Sciences. 2018.
@article{b08af3ec88174fa9a8da75e48bca1865,
title = "MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy",
abstract = "Cardiovascular disease (CVD) is a major cause of death globally. Addressing cardiovascular risk factors, particularly dyslipidemia, represents the most robust clinical strategy towards reducing the CVD burden. Statins inhibit 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and represent the main therapeutic approach for lowering cholesterol and reducing plaque formation/rupture. The protective effects of statins extend beyond lowering cholesterol. MicroRNAs (miRNAs or miRs), small noncoding regulatory RNAs, likely mediate the positive pleiotropic effects of statins via modulation of lipid metabolism, enhancement of endothelial function, inhibition of inflammation, improvement of plaque stability, and immune regulation. miRNAs are implicated in statin-related interindividual variations in therapeutic response, directly via HMG-CoA reductase, or indirectly through targeting cytochrome P450 3A (CYP3A) functionality and proprotein convertase subtilisin/kexin type9 (PCSK9) biology.",
keywords = "cardiovascular disease, interindividual variation, microRNAs, pleiotropic effects, Statins",
author = "Mohammad Mohajeri and Maciej Banach and Stephen Atkin and Butler, {Alexandra E.} and Massimiliano Ruscica and Watts, {Gerald F.} and Amirhossein Sahebkar",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.tips.2018.09.005",
language = "English",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - MicroRNAs

T2 - Novel Molecular Targets and Response Modulators of Statin Therapy

AU - Mohajeri, Mohammad

AU - Banach, Maciej

AU - Atkin, Stephen

AU - Butler, Alexandra E.

AU - Ruscica, Massimiliano

AU - Watts, Gerald F.

AU - Sahebkar, Amirhossein

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cardiovascular disease (CVD) is a major cause of death globally. Addressing cardiovascular risk factors, particularly dyslipidemia, represents the most robust clinical strategy towards reducing the CVD burden. Statins inhibit 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and represent the main therapeutic approach for lowering cholesterol and reducing plaque formation/rupture. The protective effects of statins extend beyond lowering cholesterol. MicroRNAs (miRNAs or miRs), small noncoding regulatory RNAs, likely mediate the positive pleiotropic effects of statins via modulation of lipid metabolism, enhancement of endothelial function, inhibition of inflammation, improvement of plaque stability, and immune regulation. miRNAs are implicated in statin-related interindividual variations in therapeutic response, directly via HMG-CoA reductase, or indirectly through targeting cytochrome P450 3A (CYP3A) functionality and proprotein convertase subtilisin/kexin type9 (PCSK9) biology.

AB - Cardiovascular disease (CVD) is a major cause of death globally. Addressing cardiovascular risk factors, particularly dyslipidemia, represents the most robust clinical strategy towards reducing the CVD burden. Statins inhibit 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and represent the main therapeutic approach for lowering cholesterol and reducing plaque formation/rupture. The protective effects of statins extend beyond lowering cholesterol. MicroRNAs (miRNAs or miRs), small noncoding regulatory RNAs, likely mediate the positive pleiotropic effects of statins via modulation of lipid metabolism, enhancement of endothelial function, inhibition of inflammation, improvement of plaque stability, and immune regulation. miRNAs are implicated in statin-related interindividual variations in therapeutic response, directly via HMG-CoA reductase, or indirectly through targeting cytochrome P450 3A (CYP3A) functionality and proprotein convertase subtilisin/kexin type9 (PCSK9) biology.

KW - cardiovascular disease

KW - interindividual variation

KW - microRNAs

KW - pleiotropic effects

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85053706503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053706503&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2018.09.005

DO - 10.1016/j.tips.2018.09.005

M3 - Article

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

ER -